Browse courses by:
By: Jason Bacharach, MD, Michael A. Singer, MD and Charles Wykoff, MD
This course has expired. You can still review the content but course credit is no longer available.
The target audience for this program is retina specialists.
Upon completion of this activity, the participant should be able to:
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, Retina Today and New Retina MD. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. ™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Grantor Statement
This continuing medical education activity is supported through an unrestricted educational grant from Allergan.
It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty members have the following financial relationships with commercial interests:
Jason Bacharach, MD has had a financial agreement or affiliation during the past year with the following commercial interest(s) in the form of Consultant/Advisory Board/Speaker’s Bureau: Aerie Pharmaceuticals; Alcon, Allergan, Inc.; Glaukos Corporation; Lumenis; and Sucampo Pharmaceuticals, Inc. Stock Shareholder: Glaukos Corporation.
Michael A. Singer, MD has had a financial agreement or affiliation during the past year with the following commercial interest(s) in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Inc.; Genentech, Inc.; and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Aerpio Therapeutics; Allergan, Inc.; Ampio Pharmaceuticals, Inc.; Genentech, Inc.; Ohr Pharmaceutical, Inc.; and Regeneron Pharmaceuticals, Inc.
Charles Wykoff, MD has had a financial agreement or affiliation during the past year with the following commercial interest(s) in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon Laboratories, Inc.; Alimera Sciences, Inc.; Allergan, Inc.; Bayer; Clearside Biomedical, Inc.; DORC International; Genentech, Inc.; ONL Therapeutics; Regeneron Pharmaceuticals, Inc.; and ThromboGenics, Inc. Grant/Research Support: Acucela; Alcon Laboratories, Inc.; Allegro Optical Limited; Allergan, Inc.; Ampio Pharmaceuticals; Apellis Pharmaceutical; Bayer; Clearside Biomedical, Inc.; Genentech, Inc.; Iconic Therapeutics; pSivida; Opthotech Corportion; Regeneron Pharmaceuticals, Inc.; Santeen Pharmaceutical Co., Ltd; ThromboGenics, Inc.; and Xoma.
Cheryl Cavanaugh, MS, Evolve Medical Education LLC; Emily Feinman, Retina Today and New Retina MD; and Michelle Dalton, Writer; have no real or apparent conflicts of interest to report.
Rishi Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech, Inc; Regeneron Pharmaceuticals, Inc.; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.